Exchange: NASDAQ·Updated 07:34 PM EDT
LXEO logo

LXEOLexeo Therapeutics Inc.

$4.93
$0.05
(1.00%)
Today
Closed $4.93
$0.35
(7.10%)
After Hours
EarningsAug 13
Mkt Cap$387.11M
Vol1.48M
59

Bullish Sentiment

How do you feel about LXEO?

News
all
press releases
Why Is Lexeo Therapeutics Stock Gaining Monday?
Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment set to begin in June 2026.read more...
Benzinga
News Placeholder
More News
News Placeholder
Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday
Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-lexeo-therapeutics-inc-stock...
MarketBeat
News Placeholder
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Brokerages
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one...
MarketBeat
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen cut Lexeo Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Should You Buy?
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Here's What Happened...
MarketBeat
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $312,950.00 in Stock
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average...
MarketBeat
News Placeholder
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 55,000 Shares of Stock
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of the firm's stock in a transaction dated Monday, April 6th. The shares were sold at an average...
MarketBeat
News Placeholder
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are presently covering the stock, MarketBeat.com...
MarketBeat
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Issues Quarterly Earnings Results
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.03...
MarketBeat
News Placeholder
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday
Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 23. (View Earnings Report at...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.